Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Ticker SymbolSPRC
Company nameScisparc Ltd
IPO dateDec 22, 2021
CEOMr. Amitay Weiss
Number of employees2
Security typeOrdinary Share
Fiscal year-endDec 22
Address20 Raul Wallenberg Street, Tower A
CityTEL AVIV-YAFO
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code6971916
Phone97236103100
Websitehttps://scisparc.com/
Ticker SymbolSPRC
IPO dateDec 22, 2021
CEOMr. Amitay Weiss
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data